Although CHRI has had a few weak quarters recently, overall they're a pretty profitable company with good revenue. What's been hard in attracting investors is that it's a Chinese company.
That, I think, was part of the draw for CHRI trying to merge/buy HBRM. They both are involved with herbal medicine, but getting a U.S. foothold would have been very beneficial for CHRI, IMO.